A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease
The individualized staging system can accurately assess disease severity, enabling risk stratification at ultra-early pathological stages and facilitating precise AD management.
Authors
- Kun Zhao (ORCID: https://orcid.org/0000-0002-5196-100X)
- S Q Yan
- Bo Zhou (ORCID: https://orcid.org/0000-0001-6682-0624)
- Zhifa Zhang
- Jie Lu
- Ying Han
- Yan Chen
- Yong Liu
- Zhengluan Liao
- Zhuangzhuang Li
- Pan Wang
- Dawei Wang
- Xi Zhang
Institutions
- Beijing University of Posts and Telecommunications (CN)
- Capital Medical University (CN)
- Hainan University (CN)
- Chinese PLA General Hospital (CN)
- Tianjin Huanhu Hospital (CN)
- Chinese Institute for Brain Research (CN)
- Zhejiang Provincial People's Hospital (CN)
- Inspur (China) (CN)
- Qilu Hospital of Shandong University (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1186/s12916-026-04674-6
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Disease Neuroimaging Initiative
- National Natural Science Foundation of China
- Beijing University of Posts and Telecommunications
- Tianjin Municipal Education Commission
- National Institutes of Health
- Beijing Nova Program
- National Institute on Aging